July 15, 2016
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.
Contact us if you’re interested in a copy of the presentation.
Preclinical oncology studies are a critical step in developing effective cancer therapies. Patient-derived xenograft (PDX) models have become a ...
In oncology, evaluating treatment efficacy often relies on standardized criteria such as RECIST (Response Evaluation Criteria in Solid Tumors), which ...
The evolving complexity of oncology drug development demands an equally sophisticated approach to understanding the tumor microenvironment and its ...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
© 2024 Translational Drug Development. All Rights Reserved. Terms and Conditions | Privacy Policy
